Brinzolamide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Brinzolamide: From Open-Angle Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Brinzolamide is a topical carbonic anhydrase inhibitor originally used to lower eye pressure in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be useful for primary hereditary glaucoma, but no clinical trials and no publications specific to this condition were found, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma; ocular hypertension |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 99.48% |
| Evidence Level | L5 (model prediction only) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Brinzolamide inhibits carbonic anhydrase II in the ciliary epithelium, the tissue that produces aqueous humor. Less aqueous humor means lower intraocular pressure (IOP). Detailed mechanism-of-action data were not available in the data compiled for this report, so this explanation comes from the drug's known pharmacology.
Primary hereditary glaucoma is also a pressure-driven optic nerve disease, so lowering IOP is mechanistically plausible. In practice, this prediction is an extension of the approved glaucoma use rather than a distinct new use. The high score likely reflects how closely related the two diseases are in the knowledge graph, not independent evidence of benefit in hereditary forms.
Other predictions in the same analysis are much closer to the approved use and have far more evidence:
- Open-angle glaucoma has many completed Phase 3 and Phase 4 trials, including brinzolamide/brimonidine and brinzolamide/timolol fixed combinations and generic equivalence studies.
- Glaucoma (general) includes a Phase 3 pediatric study (NCT00061516). Only the evidence base for this label is relevant to hereditary or childhood forms.
Clinical Trial Evidence
Currently no related clinical trials registered for primary hereditary glaucoma.
Literature Evidence
Currently no related literature available for primary hereditary glaucoma.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN11029P | AZOPT Ophthalmic Suspension 1% | Solution |
| SIN17215P | BRITIL Eye Drops, Suspension 1% w/v | Suspension, sterile |
| SIN15085P | SIMBRINZA Eye Drops, Suspension 10 mg/ml + 2 mg/ml | Suspension, sterile |
| SIN13802P | Azarga 10 mg/ml + 5 mg/ml Eye Drops, Suspension | Suspension, sterile |
All four registrations are currently valid. The registry did not provide approved indication text for them.
Safety Considerations
Drug Interactions: The interaction screen returned 32 potential interactions, none with a severity rating. Examples include:
- Proton pump inhibitors (pantoprazole, omeprazole, lansoprazole)
- Corticosteroids (prednisone, prednisolone, dexamethasone, triamcinolone)
- Statins (simvastatin, rosuvastatin)
- Warfarin and clopidogrel
- Antihistamines (cetirizine, fexofenadine)
Because severity is unrated, these entries should be reviewed before any clinical conclusion.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there are no trials or publications for primary hereditary glaucoma. Primary treatment for congenital and hereditary glaucoma is usually surgical, so topical IOP-lowering would at most be an adjunct or temporary measure. The strongly supported uses (open-angle glaucoma and ocular hypertension) are already on-label, so this is not true repurposing.
To proceed, the following is needed:
- Targeted literature review of carbonic anhydrase inhibitors in hereditary and pediatric glaucoma
- Review of the pediatric safety and efficacy data (NCT00061516) for relevance to hereditary forms
- Package insert warnings and contraindications, in particular for pediatric use
- Severity grading of the potential drug interactions
- Clinical expert input on whether topical brinzolamide has a role as adjunct therapy alongside surgery
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.